Maria Saur Svane

Maria Saur Svane

Auto-generated profile, based on publicly available information

Maria Saur Svane

Copenhagen University Hospital Hvidovre

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
Jens HolstJens Holst
Jens Holst
SMSten Madsbad
Sten Madsbad
KBKirstine Nyvold Bojsen-Møller
Kirstine Nyvold Bojsen-Møller
MSMaria Saur Svane
Maria Saur Svane
NJNils Bruun Jørgensen
Nils Bruun Jørgensen
CMChristoffer Martinussen
Christoffer Martinussen
Gastric bypass surgery leads to profound changes in the secretion of gut hormones with effects on metabolism, appetite, and food intake. Here, we discuss their contributions to the improvement in glucose tolerance and the weight loss that results from the operations. We find that the improved glucose tolerance is due the following events: a negative energy balance and resulting weight loss, which improve first hepatic and later peripheral insulin sensitivity, in combination with increased postprandial insulin secretion elicited particularly by exaggerated glucagon-like peptide-1 responses. The weight loss is due to loss of appetite resulting in reduced energy intake, and we find it probable that this process is driven by exaggerated secretion of appetite-regulating gut hormones including, but probably not limited to, glucagon-like peptide-1 and peptide-YY. The increased secretion is due to an accelerated exposure to and absorption of nutrients in the small intestine. This places the weight loss and the gut hormones in key positions with respect to the metabolic improvements after bypass surgery.

30 August 2016 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
MSM S Svane
M S Svane
NJN B Jørgensen
N B Jørgensen
KBKirstine Nyvold Bojsen-Møller
Kirstine Nyvold Bojsen-Møller
CDC Dirksen
C Dirksen
SNS Nielsen
S Nielsen
Jens HolstJens Holst
Jens Holst

1 May 2019 in Gastroenterology
Verified
Journal Article
Open access
PDF file
MSMaria S. Svane
Maria S. Svane
KBKirstine N. Bojsen-Møller
Kirstine N. Bojsen-Møller
CMChristoffer Martinussen
Christoffer Martinussen
CDCarsten Dirksen
Carsten Dirksen
JMJan L. Madsen
Jan L. Madsen
SMSten Madsbad
Sten Madsbad
Background & Aims Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) induce substantial weight loss and improve glycemic control in patients with type 2 diabetes, but it is not clear whether these occur via the same mechanisms. We compared absorption rates of glucose and protein, as well as profiles of gastro-entero-pancreatic hormones, in patients who had undergone SG or RYGB vs controls. Methods We performed a cross-sectional study of 12 patients who had undergone sleeve gastrectomy, 12 patients who had undergone RYGB, and 12 individuals who had undergone neither surgery (controls), all in Denmark. Study participants were matched for body mass index, age, sex, and postoperative weight loss, and all had stable weights. They received continuous infusions of stable isotopes of glucose, glycerol, phenylalanine, tyrosine, and urea before and during a mixed meal containing labeled glucose and intrinsically phenylalanine-labeled caseinate. Blood samples were collected for 6 hours, at 10- to 60-minute intervals, and analyzed. Results The systemic appearance of ingested glucose was faster after RYGB and SG vs controls; the peak glucose appearance rate was 64% higher after RYGB, and 23% higher after SG (both P < .05); the peak phenylalanine appearance rate from ingested casein was 118% higher after RYGB (P < .01), but similar between patients who had undergone SG and controls. Larger, but more transient increases in levels of plasma glucose and amino acids were accompanied by higher secretion of insulin, glucagon-like peptide 1, peptide YY, and cholecystokinin after RYGB, whereas levels of ghrelin were lower after SG, compared with RYGB and controls. Total 6-hour oral recovery of ingested glucose and protein was comparable among groups. Conclusions Postprandial glucose and protein absorption and gastro-entero-pancreatic hormone secretions differ after SG and RYGB. RYGB was characterized by accelerated absorption of glucose and amino acids, whereas protein metabolism after SG did not differ significantly from controls, suggesting that different mechanisms explain improved glycemic control and weight loss after these surgical procedures. ClinicalTrials.gov ID NCT03046186.

26 February 2019 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
SSSine Paasch Schiellerup
Sine Paasch Schiellerup
KSKirsa Skov-Jeppesen
Kirsa Skov-Jeppesen
JWJohanne Agerlin Windeløv
Johanne Agerlin Windeløv
MSMaria Saur Svane
Maria Saur Svane
JHJens Juul Holst
Jens Juul Holst
MRmette rosenkilde
mette rosenkilde
Bone homeostasis displays a circadian rhythm with increased resorption during the night time as compared to day time, a difference that seems—at least partly—to be caused by food intake during the day. Thus, ingestion of a meal results in a decrease in bone resorption, but people suffering from short bowel syndrome lack this response. Gut hormones, released in response to a meal, contribute to this link between the gut and bone metabolism. The responsible hormones appear to include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), known as incretin hormones due to their role in regulating glucose homeostasis by enhancing insulin release in response to food intake. They interact with their cognate receptors (GIPR and GLP-1R), which are both members of the class B G protein-coupled receptors (GPCRs), and already recognized as targets for treatment of metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide-2 (GLP-2), secreted concomitantly with GLP-1, acting via another class B receptor (GLP-2R), is also part of this gut-bone axis. Several studies, including human studies, have indicated that these three hormones inhibit bone resorption and, moreover, that GIP increases bone formation. Another hormone, peptide YY (PYY), is also secreted from the enteroendocrine L-cells (together with GLP-1 and GLP-2), and acts mainly via interaction with the class A GPCR NPY-R2. PYY is best known for its effect on appetite regulation, but recent studies have also shown an effect of PYY on bone metabolism. The aim of this review is to summarize the current knowledge of the actions of GIP, GLP-1, GLP-2, and PYY on bone metabolism, and to discuss future therapies targeting these receptors for the treatment of osteoporosis.

1 August 2019 in Bone
Verified
Journal Article
Closed access
KSKirsa Skov-Jeppesen
Kirsa Skov-Jeppesen
MSMaria S. Svane
Maria S. Svane
CMChristoffer Martinussen
Christoffer Martinussen
MGMaria B.N. Gabe
Maria B.N. Gabe
LGLærke S. Gasbjerg
Lærke S. Gasbjerg
BHBolette Hartmann
Bolette Hartmann

1 April 2016 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
MSMaria S. Svane
Maria S. Svane
KBKirstine Nyvold Bojsen-Møller
Kirstine Nyvold Bojsen-Møller
SNSigne Nielsen
Signe Nielsen
NJNils B. Jørgensen
Nils B. Jørgensen
CDCarsten Dirksen
Carsten Dirksen
SMSten Madsbad
Sten Madsbad
Exaggerated secretion of glucagon-like peptide 1 (GLP-1) is important for postprandial glucose tolerance after Roux-en-Y gastric bypass (RYGB), whereas the role of glucose-dependent insulinotropic polypeptide (GIP) remains to be resolved. We aimed to explore the relative importance of endogenously secreted GLP-1 and GIP on glucose tolerance and β-cell function after RYGB. We used DPP-4 inhibition to enhance concentrations of intact GIP and GLP-1 and the GLP-1 receptor antagonist exendin-(9–39) (Ex-9) for specific blockage of GLP-1 actions. Twelve glucose-tolerant patients were studied after RYGB in a randomized, placebo-controlled, 4-day crossover study with standard mixed-meal tests and concurrent administration of placebo, oral sitagliptin, Ex-9 infusion, or combined Ex-9-sitagliptin. GLP-1 receptor antagonism increased glucose excursions, clearly attenuated β-cell function, and aggravated postprandial hyperglucagonemia compared with placebo, whereas sitagliptin had no effect despite two- to threefold increased concentrations of intact GLP-1 and GIP. Similarly, sitagliptin did not affect glucose tolerance or β-cell function during GLP-1R blockage. This study confirms the importance of GLP-1 for glucose tolerance after RYGB via increased insulin and attenuated glucagon secretion in the postprandial state, whereas amplification of the GIP signal (or other DPP-4-sensitive glucose-lowering mechanisms) did not appear to contribute to the improved glucose tolerance seen after RYGB.